KATHERINE GRAAP: Open Payments
NPI 1366208894 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,164 in 44 payments from 15 companies in 2025. Trend: 2023 $13 · 2024 $2,441 · 2025 $2,164
Food & beverage: $2,004Education: $160
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 6 | $348 |
| Syndax Pharmaceuticals, Inc. | 5 | $345 |
| GlaxoSmithKline, LLC. | 8 | $329 |
| SOBI, INC | 6 | $272 |
| AstraZeneca Pharmaceuticals LP | 5 | $258 |
| ABBVIE INC. | 3 | $236 |
| Lilly USA, LLC | 2 | $87 |
| Adaptive Biotechnologies Corporation | 1 | $79 |
| Celgene Corporation | 2 | $53 |
| Teleflex LLC | 1 | $30 |
Products named: OJJAARA, Vonjo, CALQUENCE, Cresemba, REVUFORJ, VENCLEXTA, clonoSEQ, Xospata.
Industry payments across TX — which companies pay providers there.
